Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for chronic ischaemic chest pain
ACTRN12614000622606Phase 2Not yet recruiting
- Sponsor
- Creyos
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in Chronic Coronary Syndrome (CCS), sponsored by Creyos. Primary endpoint: Chest pain intensity. Planned start Jul 2014; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on ACTRN12614000622606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000622606.